IRVINE, Calif. -- (Business Wire)
Khang & Khang LLP (the “Firm”) announces that it is investigating claims
against Lion Biotechnologies, Inc. (“Lion” or the “Company”) (Nasdaq:
LBIO) concerning possible violations of federal securities laws.
If you purchased shares of Lion and want more information, please
contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman
Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by e-mail at joon@khanglaw.com.
The investigation focuses on whether Lion and certain of its officers
and/or directors violated federal securities laws. On April 10, 2017,
the Securities & Exchange Commission found that between September 2013
and March 2014, the Company’s former CEO, Manish Singh, misled investors
by commissioning over 10 internet publications and 20 widely distributed
emails promoting Lion to potential investors that purported to be
independent from the company when they were actually paid promotions.
If you have any questions concerning this notice or your rights, please
contact Joon M. Khang, a prominent litigator for almost two decades, by
telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516006344/en/
Contacts:
Khang & Khang LLP
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
Source: Khang & Khang LLP
© 2024 Canjex Publishing Ltd. All rights reserved.